Shares of CRISPR Therapeutics (NASDAQ:CRSP) were on track to snap six straight days of gains, as the stock fell more than 4% ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.

We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where ...

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $82.00 in a report ...

Vontobel Holding Ltd. trimmed its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 11.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 15,068 shares of the ...

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...

Citi analyst Yigal Nochomovitz maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...